CAS 179324-69-7

Bortezomib

Description:

Bortezomib is a proteasome inhibitor primarily used in the treatment of multiple myeloma and certain types of lymphoma. It is a synthetic compound that belongs to the class of boronic acid derivatives. The chemical formula of Bortezomib is C19H25BoroN4O4, and it features a boron atom that plays a crucial role in its mechanism of action, which involves the inhibition of the proteasome, a cellular complex responsible for degrading ubiquitinated proteins. This inhibition leads to the accumulation of pro-apoptotic factors and cell cycle regulators, ultimately inducing apoptosis in cancer cells. Bortezomib is administered via intravenous or subcutaneous injection and is known for its side effects, which may include peripheral neuropathy, gastrointestinal issues, and hematological toxicities. Its pharmacokinetics involve rapid absorption and distribution, with a half-life that allows for effective dosing schedules. Overall, Bortezomib represents a significant advancement in targeted cancer therapy, showcasing the potential of small molecules in the treatment of hematological malignancies.

Formula: C₁₉H₂₅BN₄O₄

InChI: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1

InChI key: InChIKey=GXJABQQUPOEUTA-RDJZCZTQSA-N

SMILES: [C@H](CC1=CC=CC=C1)(C(N[C@@H](CC(C)C)B(O)O)=O)NC(=O)C=2C=NC=CN2

Synonyms:

• B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
• Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
• Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
• Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-
• Bortezomib for research
• Bortizomib
• Brotezamide
• Dpba
• Ldp 341
• Mg 341
• Mln 341
• N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
• N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide
• NSC 681239
• PS 341 (pharmaceutical)
• Ps 314
• Ps 341
• Radiciol
• Velcade

Bortezomib

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purity: >98.0%(HPLC)

Color and Shape: White to Almost white powder to crystal

Molecular weight: 384.24

Ref: 3B-B5741

Bortezomib, 98%

CAS: 179324-69-7

Bortezomib, 179324-69-7, is a peptidic boronic acid analog and antineoplastic agent which turns off cell signaling pathways through 26S proteasome inhibition. Learn more.

Formula: C₁₉H₂₅BN₄O₄

Purity: 98%

Color and Shape: White to off-white, Powder or crystals or crystalline powder

Molecular weight: 384.24

Ref: 02-J60378

Bortezomib

CAS: 179324-69-7

Bortezomib

Formula: C₁₉H₂₅BN₄O₄

Purity: 98% (nmr) (Typical Value in Batch COA)

Color and Shape: Solid

Molecular weight: 384.23719

Ref: 54-BISN0125

Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 384.2372

Ref: IN-DA0026XG

Bortezomib

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purity: ≥ 98.0%

Color and Shape: White to off-white powder or solid

Molecular weight: 384.24

Ref: 7W-GP0262

Bortezomib

CAS: 179324-69-7

Bortezomib

Formula: C₁₉H₂₅BN₄O₄

Purity: ≥95%

Molecular weight: 384.24

Ref: 54-BUP15505

Bortezomib [Optimized for Cell Culture]

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purity: >98.0%(HPLC)

Color and Shape: White to Almost white powder to crystal

Molecular weight: 384.24

Ref: 3B-B6775

(1R,2S)-Bortezomib

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Molecular weight: 384.24

Ref: 4Z-B-4697

Bortezomib

CAS: 179324-69-7

Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective.

Formula: C₁₉H₂₅BN₄O₄

Purity: 97.79% - >99.99%

Color and Shape: White Solid

Molecular weight: 384.24

Ref: TM-T2399

Bortezomib

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Molecular weight: 384.24

Ref: ST-EA-CP-B34000

Bortezomib-D8 (Major)

Controlled Product

CAS: 179324-69-7

Applications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86%
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)

Formula: C₁₉H₁₇D₈BN₄O₄

Color and Shape: Neat

Molecular weight: 392.29

Ref: TR-B675702

Bortezomib

Controlled Product

CAS: 179324-69-7

Stability Hygroscopic and Moisture Sensitive
Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);

Formula: C₁₉H₂₅BN₄O₄

Color and Shape: Neat

Molecular weight: 384.24

Ref: TR-B675700

Bortezomib

CAS: 179324-69-7

Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.

Formula: C₁₉H₂₅BN₄O₄

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 384.24 g/mol

Ref: 3D-FM19000

Bortezomib - Bio-X ™

CAS: 179324-69-7

Bortezomib is a selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating t-cell lymphomas and multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.

Formula: C₁₉H₂₅BN₄O₄

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 384.24 g/mol

Ref: 3D-BB164258

Bortezomib

CAS: 179324-69-7

Purity: 98%

Molecular weight: 384.24

Ref: 10-M06307